These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 19194363

  • 1. DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
    Fathallah H.
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):806-8. PubMed ID: 19194363
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA.
    Adv Pediatr; 1996 Nov; 43():309-34. PubMed ID: 8794181
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.
    Cao H.
    Hematology; 2004 Jun; 9(3):223-33. PubMed ID: 15204104
    [Abstract] [Full Text] [Related]

  • 4. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM, Taher AT, Cappellini MD, Sankaran VG.
    Blood; 2013 Mar 21; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [Abstract] [Full Text] [Related]

  • 5. Approaches to the reactivation of hemoglobin F as a treatment for sickle cell disease.
    DeSimone J.
    Clin Adv Hematol Oncol; 2004 Jan 21; 2(1):23-4. PubMed ID: 16163154
    [No Abstract] [Full Text] [Related]

  • 6. DNA hypo-methylating agents and sickle cell disease.
    Saunthararajah Y, Lavelle D, DeSimone J.
    Br J Haematol; 2004 Sep 21; 126(5):629-36. PubMed ID: 15327513
    [Abstract] [Full Text] [Related]

  • 7. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
    Dover GJ, Charache S, Boyer SH.
    Trans Assoc Am Physicians; 1984 Sep 21; 97():140-5. PubMed ID: 6085527
    [No Abstract] [Full Text] [Related]

  • 8. Therapies to increase fetal hemoglobin in sickle cell disease.
    Steinberg MH.
    Curr Hematol Rep; 2003 Mar 21; 2(2):95-101. PubMed ID: 12901139
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Seeking a way to alleviate sickle cell disease.
    Mitka M.
    JAMA; 2003 Mar 21; 288(16):1970. PubMed ID: 12387636
    [No Abstract] [Full Text] [Related]

  • 12. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 13. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 14; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 14. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
    Italia KY, Jijina FF, Chandrakala S, Nadkarni AH, Sawant P, Ghosh K, Colah RB.
    J Clin Pharmacol; 2010 Feb 14; 50(2):231-4. PubMed ID: 19797538
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hydroxyurea and sickle cell disease.
    Orringer EP, Parker JC.
    Hematol Pathol; 1992 Feb 14; 6(4):171-8. PubMed ID: 1283391
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacologic induction of fetal hemoglobin production.
    Atweh G, Fathallah H.
    Hematol Oncol Clin North Am; 2010 Dec 14; 24(6):1131-44. PubMed ID: 21075284
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.